PT  - JOURNAL ARTICLE
AU  - HIDEKAZU KURAMOCHI
AU  - TAKESHI YAMADA
AU  - YOICHIRO YOSHIDA
AU  - AKIHISA MATSUDA
AU  - HIROHIKO KAMIYAMA
AU  - CHIHIRO KOSUGI
AU  - KEIICHIRO ISHIBASHI
AU  - ATSUKO FUKAZAWA
AU  - KEISUKE IHARA
AU  - HIROMICHI SONODA
AU  - KAZUHIKO YOSHIMATSU
AU  - HIROSHI YOSHIDA
AU  - SUGURU HASEGAWA
AU  - KAZUHIRO SAKAMOTO
AU  - HIDEYUKI ISHIDA
AU  - KEIJI KODA
AU  - On behalf of the TAS CC3 Study Group
TI  - The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
AID  - 10.21873/anticanres.15098
DP  - 2021 Jun 01
TA  - Anticancer Research
PG  - 3131--3137
VI  - 41
IP  - 6
4099  - http://ar.iiarjournals.org/content/41/6/3131.short
4100  - http://ar.iiarjournals.org/content/41/6/3131.full
SO  - Anticancer Res2021 Jun 01; 41
AB  - Background/Aim: Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3rd-line treatment. Patients and Methods: We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc analysis. Results: Receiver operating characteristic curve analyses of the 3 inflammation-based scores versus DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS). Conclusion: The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment.